Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Serological lymphocytic activity and patient-reported outcomes in Sjögren's syndrome.

Jülich M, Kanne AM, Sehnert B, Budweiser S, Voll RE, Kollert F.

Clin Rheumatol. 2018 Sep;37(9):2361-2366. doi: 10.1007/s10067-018-4159-2. Epub 2018 Jun 1.

PMID:
29858711
2.

Sleep apnea in Sjögren's syndrome potentially influences the EULAR Sjögren's syndrome patient reported index.

Jülich M, Budweiser S, Thoden J, Voll RE, Kollert F.

Mod Rheumatol. 2018 Aug 13:1-3. doi: 10.1080/14397595.2018.1467526. [Epub ahead of print] No abstract available.

PMID:
29669457
3.

Retinal Vessel Diameters and Physical Activity in Patients With Mild to Moderate Rheumatic Disease Without Cardiovascular Comorbidities.

Deiseroth A, Marcin T, Berger C, Infanger D, Schäfer J, Bannert B, Schmidt-Trucksäss A, Voll RE, Kyburz D, Hanssen H.

Front Physiol. 2018 Mar 9;9:176. doi: 10.3389/fphys.2018.00176. eCollection 2018.

4.

Synthesis and Evaluation of Pyridyloxypyridyl Indole Carboxamides as Potential PET Imaging Agents for 5-HT2C Receptors.

Zeng F, Nye JA, Voll RJ, Howell L, Goodman MM.

ACS Med Chem Lett. 2018 Feb 5;9(3):188-192. doi: 10.1021/acsmedchemlett.7b00443. eCollection 2018 Mar 8.

PMID:
29541358
5.

Agonistic Autoantibodies to the β2-Adrenergic Receptor Involved in the Pathogenesis of Open-Angle Glaucoma.

Jünemann A, Hohberger B, Rech J, Sheriff A, Fu Q, Schlötzer-Schrehardt U, Voll RE, Bartel S, Kalbacher H, Hoebeke J, Rejdak R, Horn F, Wallukat G, Kunze R, Herrmann M.

Front Immunol. 2018 Feb 12;9:145. doi: 10.3389/fimmu.2018.00145. eCollection 2018.

6.

Re(CO)3([18F]FEDA), a novel 18F PET renal tracer: Radiosynthesis and preclinical evaluation.

Lipowska M, Jarkas N, Voll RJ, Nye JA, Klenc J, Goodman MM, Taylor AT.

Nucl Med Biol. 2018 Mar;58:42-50. doi: 10.1016/j.nucmedbio.2017.12.001. Epub 2017 Dec 27.

PMID:
29367095
7.

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.

Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, Voll RE, Elbez Y, Rauch C.

Arthritis Res Ther. 2018 Jan 2;20(1):1. doi: 10.1186/s13075-017-1488-5.

8.

Radiochemical Synthesis and Evaluation of 13N-Labeled 5-Aminolevulinic Acid for PET Imaging of Gliomas.

Pippin AB, Voll RJ, Li Y, Wu H, Mao H, Goodman MM.

ACS Med Chem Lett. 2017 Nov 15;8(12):1236-1240. doi: 10.1021/acsmedchemlett.7b00311. eCollection 2017 Dec 14.

PMID:
29259740
9.

Association of High Mobility Group Box Chromosomal Protein 1 and Receptor for Advanced Glycation End Products Serum Concentrations With Extraglandular Involvement and Disease Activity in Sjögren's Syndrome.

Kanne AM, Jülich M, Mahmutovic A, Tröster I, Sehnert B, Urbonaviciute V, Voll RE, Kollert F.

Arthritis Care Res (Hoboken). 2018 Jun;70(6):944-948. doi: 10.1002/acr.23420. Epub 2018 Apr 23.

PMID:
28941024
10.

Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.

Thiel J, Troilo A, Salzer U, Schleyer T, Halmschlag K, Rizzi M, Frede N, Venhoff A, Voll RE, Venhoff N.

J Allergy Clin Immunol Pract. 2017 Nov - Dec;5(6):1556-1563. doi: 10.1016/j.jaip.2017.07.027. Epub 2017 Sep 12.

PMID:
28916432
11.

The sneaking ligand approach for cell type-specific modulation of intracellular signalling pathways.

Sehnert B, Burkhardt H, Finzel S, Dübel S, Voll RE.

Clin Immunol. 2018 Jan;186:14-20. doi: 10.1016/j.clim.2017.08.018. Epub 2017 Sep 1.

PMID:
28867254
12.

[IL-1-blockade with Anakinra during pregnancy : Retrospective analysis of efficacy and safety in female patients with familial Mediterranean fever].

Venhoff N, Voll RE, Glaser C, Thiel J.

Z Rheumatol. 2018 Mar;77(2):127-134. doi: 10.1007/s00393-017-0354-9. German.

PMID:
28752409
13.

Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination.

Gerer KF, Erdmann M, Hadrup SR, Lyngaa R, Martin LM, Voll RE, Schuler-Thurner B, Schuler G, Schaft N, Hoyer S, Dörrie J.

Ther Adv Med Oncol. 2017 Jul;9(7):451-464. doi: 10.1177/1758834017712630. Epub 2017 Jun 13.

14.

[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].

Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, Schmidt E, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kötter I, Tony HP, Holle J, Aringer M, Erler A, Behrens F, Burmester GR, Dörner T.

Z Rheumatol. 2018 Feb;77(1):28-39. doi: 10.1007/s00393-017-0330-4. German.

PMID:
28589389
15.

Whipple's disease mimicking rheumatoid arthritis can cause misdiagnosis and treatment failure.

Glaser C, Rieg S, Wiech T, Scholz C, Endres D, Stich O, Hasselblatt P, Geißdörfer W, Bogdan C, Serr A, Häcker G, Voll RE, Thiel J, Venhoff N.

Orphanet J Rare Dis. 2017 May 25;12(1):99. doi: 10.1186/s13023-017-0630-4.

16.

B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.

Thiel J, Rizzi M, Engesser M, Dufner AK, Troilo A, Lorenzetti R, Voll RE, Venhoff N.

Arthritis Res Ther. 2017 May 18;19(1):101. doi: 10.1186/s13075-017-1306-0.

17.

[Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis : Efficacy and safety analysis of a national registry (GRAID2)].

Venhoff N, Proft F, Schulze-Koops H, Holle J, Voll RE, Iking-Konert C, Jacobi AM, Henes J, Unger L, Kneitz O, Dörner T, Thiel J.

Z Rheumatol. 2018 Feb;77(1):21-27. doi: 10.1007/s00393-017-0315-3. German.

PMID:
28508096
18.

IgG4-related disease in autoimmune lymphoproliferative syndrome.

van de Ven AAJM, Seidl M, Drendel V, Schmitt-Graeff A, Voll RE, Rensing-Ehl A, Speckmann C, Ehl S, Warnatz K, Kollert F.

Clin Immunol. 2017 Jul;180:97-99. doi: 10.1016/j.clim.2017.05.003. Epub 2017 May 3.

PMID:
28478106
19.

Staphylococcus aureus bacteremia in patients with rheumatoid arthritis - Data from the prospective INSTINCT cohort.

Joost I, Kaasch A, Pausch C, Peyerl-Hoffmann G, Schneider C, Voll RE, Seifert H, Kern WV, Rieg S.

J Infect. 2017 Jun;74(6):575-584. doi: 10.1016/j.jinf.2017.03.003. Epub 2017 Mar 18.

PMID:
28322887
20.

DNA Damage Signaling Instructs Polyploid Macrophage Fate in Granulomas.

Herrtwich L, Nanda I, Evangelou K, Nikolova T, Horn V, Sagar, Erny D, Stefanowski J, Rogell L, Klein C, Gharun K, Follo M, Seidl M, Kremer B, Münke N, Senges J, Fliegauf M, Aschman T, Pfeifer D, Sarrazin S, Sieweke MH, Wagner D, Dierks C, Haaf T, Ness T, Zaiss MM, Voll RE, Deshmukh SD, Prinz M, Goldmann T, Hölscher C, Hauser AE, Lopez-Contreras AJ, Grün D, Gorgoulis V, Diefenbach A, Henneke P, Triantafyllopoulou A.

Cell. 2016 Nov 17;167(5):1264-1280.e18. doi: 10.1016/j.cell.2016.09.054. Epub 2016 Oct 27.

21.

[Lupus erythematosus - Update 2016].

Aringer M, Voll RE.

Dtsch Med Wochenschr. 2016 Nov;141(24):1785-1788. Epub 2016 Nov 30. Review. German.

PMID:
27903029
22.

Impact of tofacitinib treatment on human B-cells in vitro and in vivo.

Rizzi M, Lorenzetti R, Fischer K, Staniek J, Janowska I, Troilo A, Strohmeier V, Erlacher M, Kunze M, Bannert B, Kyburz D, Voll RE, Venhoff N, Thiel J.

J Autoimmun. 2017 Feb;77:55-66. doi: 10.1016/j.jaut.2016.10.005. Epub 2016 Oct 26.

PMID:
27793425
23.

Autoantibodies against Modified Histone Peptides in SLE Patients Are Associated with Disease Activity and Lupus Nephritis.

Dieker J, Berden JH, Bakker M, Briand JP, Muller S, Voll R, Sjöwall C, Herrmann M, Hilbrands LB, van der Vlag J.

PLoS One. 2016 Oct 25;11(10):e0165373. doi: 10.1371/journal.pone.0165373. eCollection 2016.

24.

Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus.

Morris DL, Sheng Y, Zhang Y, Wang YF, Zhu Z, Tombleson P, Chen L, Cunninghame Graham DS, Bentham J, Roberts AL, Chen R, Zuo X, Wang T, Wen L, Yang C, Liu L, Yang L, Li F, Huang Y, Yin X, Yang S, Rönnblom L, Fürnrohr BG, Voll RE, Schett G, Costedoat-Chalumeau N, Gaffney PM, Lau YL, Zhang X, Yang W, Cui Y, Vyse TJ.

Nat Genet. 2016 Aug;48(8):940-946. doi: 10.1038/ng.3603. Epub 2016 Jul 11.

25.

In Vitro Metabolic Stability and in Vivo Biodistribution of 3-Methyl-4-furoxancarbaldehyde Using PET Imaging in Rats.

Pippin AB, Mohd Arshad ZH, Voll RJ, Nye JA, Ghassabian S, Williams CM, Mancini A, Liotta DC, Smith MT, Goodman MM.

ACS Med Chem Lett. 2016 Mar 30;7(6):563-7. doi: 10.1021/acsmedchemlett.5b00410. eCollection 2016 Jun 9.

26.

[Sarcoidosis].

Frye BC, Schupp JC, Köhler TC, Voll RE, Müller-Quernheim J.

Z Rheumatol. 2016 May;75(4):389-401. doi: 10.1007/s00393-016-0086-2. Review. German.

PMID:
27146405
27.

Secondary Antibody Deficiency in Glucocorticoid Therapy Clearly Differs from Primary Antibody Deficiency.

Wirsum C, Glaser C, Gutenberger S, Keller B, Unger S, Voll RE, Vach W, Ness T, Warnatz K.

J Clin Immunol. 2016 May;36(4):406-12. doi: 10.1007/s10875-016-0264-7. Epub 2016 Mar 15.

PMID:
26980224
28.
29.

Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor.

Stehouwer JS, Birnbaum MS, Voll RJ, Owens MJ, Plott SJ, Bourke CH, Wassef MA, Kilts CD, Goodman MM.

Bioorg Med Chem. 2015 Aug 1;23(15):4286-302. doi: 10.1016/j.bmc.2015.06.036. Epub 2015 Jun 19.

30.

HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis.

Muth IE, Zschüntzsch J, Kleinschnitz K, Wrede A, Gerhardt E, Balcarek P, Schreiber-Katz O, Zierz S, Dalakas MC, Voll RE, Schmidt J.

Exp Neurol. 2015 Sep;271:189-97. doi: 10.1016/j.expneurol.2015.05.023. Epub 2015 Jun 3.

PMID:
26048613
31.

Sneaking-ligand fusion proteins attenuate serum transfer arthritis by endothelium-targeted NF-κB inhibition.

Sehnert B, Burkhardt H, May MJ, Zwerina J, Voll RE.

Methods Mol Biol. 2015;1280:579-91. doi: 10.1007/978-1-4939-2422-6_34.

PMID:
25736773
32.

The "sneaking-ligand" approach: cell-type specific inhibition of the classical NF-κB pathway.

Sehnert B, Burkhardt H, Dübel S, Voll RE.

Methods Mol Biol. 2015;1280:559-78. doi: 10.1007/978-1-4939-2422-6_33.

PMID:
25736772
33.

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.

Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A, Taddeo A, Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE.

Ann Rheum Dis. 2015 Jul;74(7):1474-8. doi: 10.1136/annrheumdis-2014-206016. Epub 2015 Feb 20.

34.

[Plasma cells].

Hiepe F, Alexander T, Voll RE.

Z Rheumatol. 2015 Feb;74(1):20-5. doi: 10.1007/s00393-014-1438-4. German.

PMID:
25616773
35.

Triggering of NF-κB in cytokine-matured human DCs generates superior DCs for T-cell priming in cancer immunotherapy.

Pfeiffer IA, Hoyer S, Gerer KF, Voll RE, Knippertz I, Gückel E, Schuler G, Schaft N, Dörrie J.

Eur J Immunol. 2014 Nov;44(11):3413-28. doi: 10.1002/eji.201344417. Epub 2014 Sep 16.

36.

A thermostable bacterial cocaine esterase rapidly eliminates cocaine from brain in nonhuman primates.

Howell LL, Nye JA, Stehouwer JS, Voll RJ, Mun J, Narasimhan D, Nichols J, Sunahara R, Goodman MM, Carroll FI, Woods JH.

Transl Psychiatry. 2014 Jul 1;4:e407. doi: 10.1038/tp.2014.48.

37.

High levels of SOX5 decrease proliferative capacity of human B cells, but permit plasmablast differentiation.

Rakhmanov M, Sic H, Kienzler AK, Fischer B, Rizzi M, Seidl M, Melkaoui K, Unger S, Moehle L, Schmit NE, Deshmukh SD, Ayata CK, Schuh W, Zhang Z, Cosset FL, Verhoeyen E, Peter HH, Voll RE, Salzer U, Eibel H, Warnatz K.

PLoS One. 2014 Jun 19;9(6):e100328. doi: 10.1371/journal.pone.0100328. eCollection 2014.

38.

T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway.

Bozec A, Zaiss MM, Kagwiria R, Voll R, Rauh M, Chen Z, Mueller-Schmucker S, Kroczek RA, Heinzerling L, Moser M, Mellor AL, David JP, Schett G.

Sci Transl Med. 2014 May 7;6(235):235ra60. doi: 10.1126/scitranslmed.3007764.

39.

Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease.

Venhoff N, Niessen L, Kreuzaler M, Rolink AG, Hässler F, Rizzi M, Voll RE, Thiel J.

Autoimmunity. 2014 Sep;47(6):401-8. doi: 10.3109/08916934.2014.914174. Epub 2014 May 6.

PMID:
24798501
40.

Introduction: B cell-mediated autoimmune diseases.

Winkler TH, Voll RE.

Semin Immunopathol. 2014 May;36(3):275-6. doi: 10.1007/s00281-014-0432-x. Epub 2014 Apr 29. No abstract available.

PMID:
24777747
41.

Loading of nuclear autoantigens prototypically recognized by systemic lupus erythematosus sera into late apoptotic vesicles requires intact microtubules and myosin light chain kinase activity.

Zirngibl M, Fürnrohr BG, Janko C, Munoz LE, Voll RE, Gregory CD, Schett G, Herrmann M.

Clin Exp Immunol. 2015 Jan;179(1):39-49. doi: 10.1111/cei.12342.

42.

Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis.

Toh ML, Bonnefoy JY, Accart N, Cochin S, Pohle S, Haegel H, De Meyer M, Zemmour C, Preville X, Guillen C, Thioudellet C, Ancian P, Lux A, Sehnert B, Nimmerjahn F, Voll RE, Schett G.

Arthritis Rheumatol. 2014 Nov;66(11):2989-3000. doi: 10.1002/art.38624.

43.

The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity.

Medgyesi D, Hobeika E, Biesen R, Kollert F, Taddeo A, Voll RE, Hiepe F, Reth M.

J Exp Med. 2014 Mar 10;211(3):427-40. doi: 10.1084/jem.20131196. Epub 2014 Mar 3.

44.

Bronchoalveolar lavage cytology resembles sarcoidosis in a subgroup of granulomatous CVID.

Kollert F, Venhoff N, Goldacker S, Wehr C, Lützen N, Voll RE, Prasse A, Warnatz K.

Eur Respir J. 2014 Mar;43(3):922-4. doi: 10.1183/09031936.00025513. No abstract available.

45.

Quantification of dopamine transporter density with [18F]FECNT PET in healthy humans.

Nye JA, Votaw JR, Bremner JD, Davis MR, Voll RJ, Camp VM, Goodman MM.

Nucl Med Biol. 2014 Mar;41(3):217-22. doi: 10.1016/j.nucmedbio.2013.12.013. Epub 2013 Dec 26.

46.

A marriage with sarcoidosis.

Kollert C, Voll RE, Kollert F.

Mod Rheumatol. 2014 May;24(3):546. doi: 10.3109/14397595.2013.874759. Epub 2014 Feb 7. No abstract available.

PMID:
24506657
47.

Oestradiol alters central 5-HT1A receptor binding potential differences related to psychosocial stress but not differences related to 5-HTTLPR genotype in female rhesus monkeys.

Michopoulos V, Perez Diaz M, Embree M, Reding K, Votaw JR, Mun J, Voll RJ, Goodman MM, Wilson M, Sanchez M, Toufexis D.

J Neuroendocrinol. 2014 Feb;26(2):80-8. doi: 10.1111/jne.12129.

48.

Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Thiel J, Hässler F, Salzer U, Voll RE, Venhoff N.

Arthritis Res Ther. 2013 Sep 24;15(5):R133. doi: 10.1186/ar4313.

49.

An improved synthesis of [11C]MENET via Suzuki coupling with [11C]methyl iodide.

Zeng F, Voll RJ, Crowe RJ, Waldrep MS, Dolph KB, Goodman MM.

J Labelled Comp Radiopharm. 2013 May 15;56(5):307-9. doi: 10.1002/jlcr.3047. Epub 2013 Apr 24.

PMID:
24285377
50.

Synthesis of a phenolic precursor and its efficient O-[18F]fluoroethylation with purified no-carrier-added [18F]2-fluoroethyl brosylate as the labeling agent.

Jarkas N, Voll RJ, Goodman MM.

J Labelled Comp Radiopharm. 2013 Sep;56(11):539-43. doi: 10.1002/jlcr.3046. Epub 2013 May 3.

PMID:
24285185

Supplemental Content

Support Center